ANDA 62755, held by Glaxosmithkline. Nafcillin Sodium.
As of Nov 16, 2026, ANDA 62755 (Nallpen), held by Glaxosmithkline, was first approved by FDA on Dec 19, 1986, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 19, 1986 | Original application | Approved | None posted |
| NallpenEQ 1GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Discontinued |
| NallpenEQ 2GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Discontinued |
| Jun 29, 1993 | Supplement 6Labeling | Approved | None posted |
| Dec 19, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters